Float Short %

18.37

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

0.29

EPS Last/This Y

0.08

EPS This/Next Y

1.84

Price

19.4

Target Price

34.38

Analyst Recom

1.25

Performance Q

70.03

Relative Volume

0.33

Beta

1.13

Ticker: URGN

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-07	URGN	13.46	0.28	0.10	58011
2025-07-08	URGN	13.71	0.28	0.05	58168
2025-07-09	URGN	13.83	0.28	1.52	58537
2025-07-10	URGN	14.64	0.28	0.13	59034
2025-07-11	URGN	14.21	0.28	0.10	59567
2025-07-14	URGN	14.47	0.28	0.69	59569
2025-07-15	URGN	14.04	0.28	0.41	59685
2025-07-16	URGN	14.3	0.28	0.13	59570
2025-07-17	URGN	15.4	0.28	0.20	59453
2025-07-18	URGN	15.29	0.28	0.04	60657
2025-07-21	URGN	15.38	0.27	0.09	29892
2025-07-22	URGN	16.94	0.26	0.10	31244
2025-07-23	URGN	18.66	0.25	0.48	32965
2025-07-24	URGN	17.97	0.27	0.64	35040
2025-07-25	URGN	18.98	0.29	0.23	35585
2025-07-28	URGN	18.88	0.29	0.77	36036
2025-07-29	URGN	18.91	0.29	1.10	36110
2025-07-30	URGN	19.21	0.30	0.03	36781
2025-07-31	URGN	19.06	0.30	0.08	36807
2025-08-01	URGN	19.4	0.30	0.10	36844
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-07	URGN	13.48	9.0	-	-2.88
2025-07-08	URGN	13.71	9.0	-	-2.88
2025-07-09	URGN	13.81	9.0	-	-2.88
2025-07-10	URGN	14.64	9.0	-	-2.88
2025-07-11	URGN	14.24	9.0	-	-2.88
2025-07-14	URGN	14.49	9.0	-	-2.88
2025-07-15	URGN	14.04	9.0	-	-2.88
2025-07-16	URGN	14.32	9.0	-	-2.88
2025-07-17	URGN	15.41	9.0	-	-2.88
2025-07-18	URGN	15.28	9.0	-	-2.88
2025-07-21	URGN	15.47	9.0	-	-2.88
2025-07-22	URGN	16.94	9.0	-	-2.88
2025-07-23	URGN	18.66	9.0	-	-2.88
2025-07-24	URGN	18.00	9.0	-	-2.88
2025-07-25	URGN	18.95	9.0	-	-2.88
2025-07-28	URGN	18.81	9.0	-	-2.88
2025-07-29	URGN	18.90	9.0	-	-2.88
2025-07-30	URGN	19.22	9.0	-	-2.88
2025-07-31	URGN	19.06	9.0	-	-2.88
2025-08-01	URGN	19.40	9.0	-	-2.88
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-07	URGN	-0.26	28.67	15.46
2025-07-08	URGN	-0.26	28.67	15.46
2025-07-09	URGN	-0.26	28.67	15.46
2025-07-10	URGN	-0.26	28.67	15.46
2025-07-11	URGN	-0.26	28.67	13.76
2025-07-14	URGN	-0.26	28.51	13.76
2025-07-15	URGN	-0.26	28.51	13.76
2025-07-16	URGN	-0.26	28.51	13.76
2025-07-17	URGN	-0.26	28.51	13.76
2025-07-18	URGN	-0.26	28.51	13.76
2025-07-21	URGN	-0.26	28.53	13.73
2025-07-22	URGN	-0.26	28.53	13.73
2025-07-23	URGN	-0.26	28.53	13.73
2025-07-24	URGN	-0.26	28.53	13.73
2025-07-25	URGN	-0.26	28.53	18.37
2025-07-28	URGN	-0.26	29.32	18.37
2025-07-29	URGN	-0.26	29.32	18.37
2025-07-30	URGN	-0.46	29.32	18.37
2025-07-31	URGN	-0.46	29.32	18.37
2025-08-01	URGN	-0.46	29.32	18.37
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.92

Avg. EPS Est. Current Quarter

-0.83

Avg. EPS Est. Next Quarter

-0.63

Insider Transactions

-0.46

Institutional Transactions

29.32

Beta

1.13

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

31.2

Max Drawdown 5-Year %

-85.4

Target Price

34.38

P/E

Forward P/E

PEG

P/S

9.76

P/B

P/Free Cash Flow

EPS

-3.18

Average EPS Est. Cur. Y

-2.88

EPS Next Y. (Est.)

-1.04

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-150.68

Relative Volume

0.33

Return on Equity vs Sector %

274.2

Return on Equity vs Industry %

292.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

UroGen Pharma Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 234

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today

news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025

marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance

stock history URGN – UroGen Pharma Ltd. invest stock market

stock prices URGN premarket after hours

ticker URGN fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: URGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y